Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

Abstract

PURPOSE To determine the maximum-tolerable dose (MTD) and to investigate the pharmacokinetics and pharmacodynamics of topotecan in a phase I study. Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. Broad preclinical activity rationalized further clinical evaluation… (More)

Topics

Cite this paper

@article{Warmerdam1995PhaseIC, title={Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.}, author={Laurence J C van Warmerdam and W. W. ten Bokkel Huinink and Sjoerd Rodenhuis and I J Koier and Brian E. Davies and Hannes Rosing and Robert A. A. Maes and J H M Beijnen}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={1995}, volume={13 7}, pages={1768-76} }